CA
NZ
UK
AU
IND
US
RMAT designation is a special FDA regulatory pathway designed to expedite the development and review of regenerative medicine therapies, including cell therapies like Allocetra, that address serious conditions with preliminary clinical evidence indicating the potential to address unmet medical needs. Companies receiving this designation …
Public stock offerings of this size relative to a company's existing market capitalization are a common but often painful reality for clinical-stage biotech companies that need substantial capital to fund ongoing and future pipeline development. While raising capital is a necessary and often value-preserving …
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, caused by deficient or dysfunctional von Willebrand factor (VWF), a protein essential for normal blood clotting. Patients with VWD can experience excessive bleeding, and current treatment options often require frequent administration, making a …
Chief Medical Officers typically play a central role in clinical-stage biotech companies, overseeing trial design, regulatory strategy, and the medical narrative presented to investors and agencies like the FDA. A departure ahead of major trial milestones can introduce execution risk, particularly if institutional knowledge …
The oversubscription of the offering, meaning investor demand exceeded the securities initially offered, is often read by the market as a strong signal of confidence in a company's near-term catalysts, and today's dramatic share price reaction suggests investors are viewing this financing as a …
This resolution is significant because it removes an overhang that had been weighing on the stock — the risk of an involuntary delisting from Nasdaq for failing to maintain minimum market value standards. Companies facing this kind of listing deficiency are typically given a …
The relatively muted share price movement today follows a recent, more significant regulatory milestone: the company's agreement with the FDA regarding its Initial Pediatric Study Plan (iPSP), noted on July 13, 2026. This agreement, required under the Pediatric Research Equity Act (PREA), allows Armata …
The $1.00 minimum bid price rule is one of Nasdaq's core continued-listing standards, designed to ensure companies trading on the exchange maintain a share price reflecting a baseline level of market confidence. Companies that fall below this threshold for an extended period are typically …
Mezigdomide, also known by its earlier designation CC-92480, is a CELMoD (cereblon E3 ligase modulator) therapy being evaluated in combination with carfilzomib and dexamethasone — a regimen referred to as MeziKd — in the SUCCESSOR-2 trial for patients with relapsed or refractory multiple myeloma. …
Spero Therapeutics disclosed a funding arrangement of $105 million on July 14, 2026 that will prolong its cash runway to the second half of 2029. The non‑recourse, non‑dilutive form of financing is poised to influence capital‑raising strategies within biotech as firms look for ways …
Please wait processing your request...